Clinical trials
Squamous Cell Carcinoma of the Skin clinical trials
Below are recruiting squamous cell carcinoma of the skin clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04988074RecruitingPhase 2
Test cemiplimab for HPV-positive throat cancer using tumor biomarkers
This Phase 2 trial studies whether cemiplimab (with or without chemotherapy first) can improve treatment for HPV-positive oropharynx throat cancer. It also uses lab “biomarkers” to help guide which treatment you get next.
Baltimore, MarylandAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT03370406RecruitingPhase 1
Test cream and injection treatment for skin squamous cell cancer
This early-phase study tests whether combining an injection into the skin lesion with a topical cream can treat squamous cell skin cancer. It may help shrink the cancer and improve control in people whose tumor is in the lower legs or feet.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03114462RecruitingPhase 1
Study of focused radiation for laryngeal cancer
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
Houston, TexasAges 18 years+ - NCT02128906RecruitingPhase 2
Radiation plus chemo choices for throat cancer, using a tumor marker
This trial compares two treatment combinations given with radiation for certain cancers of the throat. It also uses a lab test on the tumor (ERCC1) to help choose and study which treatment works better.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07227350RecruitingPhase 2
L19IL2 and L19TNF for advanced basal cell carcinoma
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
Tampa, FloridaAges 18 years+ - NCT07571551RecruitingPhase 2
Immunotherapy and targeted drug treatment for kidney cancer
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
Nanjing, JiangsuAges 18–80 - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05978284RecruitingPhase 1/Phase 2
Study of ZG006 for small cell lung cancer or neuroendocrine carcinoma
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
Zhengzhou, HenanAges 18–75 - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT04853342RecruitingPhase 3
Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Suzhou, JiangsuAges 18–75 - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT03467360RecruitingPhase 1
Adding an acetazolamide-type drug to lung cancer radiation and drugs
This Phase 1 trial tests whether blocking an enzyme (with an acetazolamide-like medicine) can be safely combined with standard treatment for small cell lung cancer that has not spread. The goal is to see if the treatment can be given safely and to learn early signs of benefit.
NiceAges 18 years+
Hear when a new Squamous Cell Carcinoma of the Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell carcinoma of the skin?
- Yes. Clin2 currently lists 431 recruiting squamous cell carcinoma of the skin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell carcinoma of the skin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell carcinoma of the skin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.